Drug release device and pulsed drug release kit

Abstract

According to an embodiment of the present application, a drug release device is provided. The drug release device may comprise: a main body part comprising a foaming part which generates gas by reacting with body fluid, and a gas accommodation part provided above the foaming part to accommodate the gas generated from the foaming part; a drug accommodation part which is provided inside the gas accommodation part and accommodates a drug in the inside thereof; and a body fluid delivery part provided below the foaming part to deliver body fluid to the foaming part, wherein after a preset period of time has elapsed in a state where the body liquid delivery part is in contact with body fluid, the body fluid delivery part delivers the body fluid to the foaming part, and when the internal pressure of the gas accommodation part increases as the gas is generated from the foaming part, the drug accommodated in the drug accommodation part is released to the outside.

Description

Drug release device and pulsed drug release kit

[0001] The present invention relates to a drug release device and a pulsed drug release kit.

[0002] Infectious diseases are caused by various pathogens, including viruses, bacteria, fungi, and parasites, and vaccination is necessary to prevent them. Vaccines consist of proteins or nucleic acids containing weakened pathogens or antigenic information; these vaccines can easily denature or lose their activity due to external environmental factors. Therefore, to maintain efficacy, vaccines must be stored at an appropriate temperature, and additional booster shots are required after vaccination. However, while booster shots must be administered at regular intervals, it is often difficult to get vaccinated on time due to various factors.

[0003] To address these issues, implantable drug delivery devices capable of releasing drugs multiple times over a certain period with a single injection are currently being developed. Most currently developed implantable devices utilize materials that automatically decompose after a certain period once implanted in the body, or release drugs via electronic circuits or batteries. However, materials that automatically decompose present problems such as difficulty in controlling the decomposition rate or excessively long decomposition times, while devices using electronic circuits or batteries present the inconvenience of requiring the user to operate the device manually and face challenges in miniaturization.

[0004] Therefore, it is necessary to develop a drug release device that can solve these problems.

[0005] The purpose of this application is to provide a drug release device and a pulsed drug release kit.

[0006] The technical problems of the present application are not limited to those mentioned above, and other unmentioned technical problems will be clearly understood by those skilled in the art from the description below.

[0007] According to an embodiment of the present application, a drug release device is provided. The drug release device comprises: a main body part including a foaming part that reacts with body fluid to generate gas; and a gas receiving part provided above the foaming part to receive the gas generated from the foaming part; a drug receiving part provided inside the gas receiving part and containing a drug; and a body fluid delivery part provided below the foaming part to deliver the body fluid to the foaming part. The body fluid delivery part delivers the body fluid to the foaming part after a preset period has elapsed upon contact with the body fluid, and when the internal pressure of the gas receiving part increases as the gas is generated from the foaming part, the drug contained in the drug receiving part may be released to the outside.

[0008] Additionally, the main body portion is provided on one side of the gas receiving portion and includes a thin film portion that shields at least one side of the gas receiving portion from the outside, and the drug receiving portion includes a soft receiving pocket in which the drug is received; and an incision portion formed to protrude toward the thin film portion from one side of the receiving pocket; and when the internal pressure of the gas receiving portion increases, the receiving pocket bends toward the thin film portion, and the incision portion cuts the thin film portion, thereby allowing the drug to be released to the outside.

[0009] Additionally, the above-mentioned fluid delivery unit includes a decomposition wick positioned such that one end is exposed to the outside and the other end faces the foaming unit, and when the fluid comes into contact with the one end, the decomposition wick is gradually decomposed by the fluid, and when the fluid reaches the other end and the other end is decomposed by the fluid, the fluid can be delivered to the foaming unit.

[0010] In addition, the length of the disassembly wick can be set by taking into account the disassembly speed of the disassembly wick and the length of the pre-set period.

[0011] In addition, the remaining portion of the disassembly wick, excluding the aforementioned end portion, may be shielded from contact with the outside.

[0012] Additionally, the foaming portion may include a foaming tablet containing a foaming material that reacts with at least one substance contained in a body fluid to generate gas; and a gas communication hole communicating the internal space of the foaming tablet and the gas receiving portion.

[0013] Additionally, the drug receiving portion contacts the inner circumference of the gas receiving portion along its circumference to divide the internal space of the gas receiving portion, and the internal space of the gas receiving portion includes a first space formed on one side of the drug receiving portion and communicating with the gas communication hole; and a second space formed on the other side of the drug receiving portion and blocking the entry of gas generated from the foaming portion, and a body fluid communication hole communicating with the second space may be formed at the top of the gas receiving portion.

[0014] In addition, the above drug release device can be implanted in the body.

[0015] According to an embodiment of the present application, a pulsed drug release kit is provided in which two or more of the drug release devices are connected.

[0016] In addition, the drug release device includes a first drug release device and a second drug release device, and the fluid delivery part of the second drug release device may be connected to the upper part of the main body of the first drug release device.

[0017] According to the embodiments of the present application, the drug can be accurately released into the body after a predetermined period has elapsed.

[0018] In addition, according to the embodiments of the present application, drugs can be released into the body within a relatively short time by adjusting the length of the disintegration wick.

[0019] In addition, according to the embodiments of the present application, the drug release delay time can be precisely controlled by considering the type and payload of the drug, thereby allowing for the diverse utilization of various drug administration schedules.

[0020] In addition, according to the embodiments of the present application, since the drug release device can be operated without electronic components, it is easy to lighten and miniaturize, making it easy to implant in the body.

[0021] The effects obtainable from the embodiments of the present application are not limited to those mentioned above, and other unmentioned effects will be clearly understood by those skilled in the art to which the present application belongs from the description below.

[0022] A brief description of each drawing is provided to help to better understand the drawings cited in the detailed description of the present application.

[0023] FIG. 1 is a perspective view of a drug release device according to an embodiment of the present application.

[0024] FIG. 2 is an exploded perspective view of a drug release device according to an embodiment of the present application.

[0025] FIG. 3 is a perspective view of a foamed portion according to an embodiment of the present application.

[0026] FIG. 4 is a cross-sectional view of a drug release device according to an embodiment of the present application.

[0027] FIG. 5 is a drawing for explaining a body fluid delivery unit according to an embodiment of the present application.

[0028] FIG. 6 is a diagram illustrating the drug release process of a drug release device according to an embodiment of the present application.

[0029] FIG. 7 is a perspective view of a pulsed drug release kit according to an embodiment of the present application.

[0030] FIG. 8 is a cross-sectional view of a pulsed drug release kit according to an embodiment of the present application.

[0031] FIG. 9 is a diagram illustrating the drug release process of a pulsed drug release kit according to an embodiment of the present application.

[0032] Hereinafter, embodiments of the present application will be described in detail with reference to the contents described in the attached drawings. Identical reference numbers or symbols presented in each drawing indicate parts or components that perform substantially the same function. For convenience of reference, the directions of up, down, left, and right described below are based on the drawings, and the scope of the rights of the present application is not limited to such directions.

[0033] In describing the technical concept of the present application, detailed descriptions of related prior art are omitted if it is determined that such descriptions would unnecessarily obscure the essence of the present application. Furthermore, numbers used in the description of the present application (e.g., First, Second, etc.) are merely identification symbols to distinguish one component from another.

[0034] The terms used herein are for the purpose of describing embodiments and are not intended to limit or / or restrict the present application. Singular expressions include plural expressions unless the context clearly indicates otherwise. When a part is described as being connected to another part in this specification, this includes not only cases where they are directly connected but also cases where they are indirectly connected with other components in between. Furthermore, when a part is described as including a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components.

[0035] Furthermore, in this application, the term "or" is intended to mean an implicit "or" rather than an exclusive "or." That is, unless otherwise specified or evident from the context, "X uses A or B" is intended to mean one of the natural implicit substitutions. In other words, if X uses A; if X uses B; or if X uses both A and B, "X uses A or B" may apply to any of these cases. Additionally, the term "and / or" as used herein should be understood to refer to and include all possible combinations of one or more of the enumerated related configurations.

[0036] Furthermore, it is intended to clarify that the classification of the components in this application is merely based on the primary function each component is responsible for. That is, two or more components described below may be combined into a single component, or a single component may be divided into two or more components based on more subdivided functions. Additionally, each component described below may additionally perform some or all of the functions performed by other components in addition to its own primary function, and it is obvious that some of the primary functions performed by each component may be exclusively performed by other components.

[0037]

[0038] FIG. 1 is a perspective view of a drug release device according to an embodiment of the present application, FIG. 2 is an exploded perspective view of a drug release device according to an embodiment of the present application, FIG. 3 is a perspective view of a foaming part according to an embodiment of the present application, and FIG. 4 is a cross-sectional view of a drug release device according to an embodiment of the present application.

[0039] Referring to FIGS. 1 to 4, the drug release device (1000) includes a main body (100), a drug receiving part (200), and a body fluid delivery part (300). The drug release device (1000) can be implanted in the body and release a drug into the body after a preset period has elapsed.

[0040] The main body (100) can increase its internal pressure by reacting with the body fluid delivered by the body fluid delivery unit (300), and can release the drug contained in the drug receiving unit (200) to the outside as the internal pressure increases.

[0041] In an embodiment, the main body (100) may include a foaming part (110) and a gas receiving part (120).

[0042] The foaming unit (110) can react with body fluids to generate gas. The gas generated from the foaming unit (110) can be transferred to the gas receiving unit (120).

[0043] In an embodiment, the foaming section (110) may include a foaming tablet (111) and a gas communication hole (112). The foaming tablet (111) may contain a foaming material that reacts with at least one substance contained in body fluid to produce gas. The gas produced by the reaction may be, for example, carbon dioxide (CO2). The gas communication hole (112) may communicate with the internal space of the foaming tablet (111) and the gas receiving section (120). The gas produced from the foaming tablet (111) may be introduced into the gas receiving section (120) through the gas communication hole (112). For example, the foaming tablet (111) may include ascorbic acid (C6H8O6), sodium bicarbonate (NaHCO3), calcium carbonate (CaCO3), sodium carbonate (Na2CO3), potassium bicarbonate (KHCO3), magnesium carbonate (MgCO3), etc., as a substance that reacts with body fluid to produce gas. For example, the effervescent tablet (111) may contain ascorbic acid (C6H8O6).

[0044] The gas receiving section (120) can receive gas generated from the foaming section (110). As gas is generated from the foaming section (110), if the internal pressure of the gas receiving section (120) increases, the drug contained in the drug receiving section (200) can be released to the outside. For example, the gas receiving section (120) may be provided above the foaming section (110), and may be provided to surround, for example, at least a part of the foaming section (110).

[0045] In an embodiment, a thin film portion (121) may be provided on one side of the gas receiving portion (120). The thin film portion (121) is provided on one side of the gas receiving portion (120) so as to shield at least one side of the gas receiving portion (120) from the outside. By the thin film portion (121), the release of the drug provided in the drug release device (1000) to the outside may be blocked, and when the thin film portion (121) is opened, the drug may be released to the outside. The thin film portion (121) may be formed of a metal thin film, for example, titanium, gold, platinum, aluminum, etc.

[0046] In an embodiment, the internal space of the gas receiving portion (120) may include a first space (122) and a second space (123). The first space (122) and the second space (123) may be formed as the internal space of the gas receiving portion (120) is divided by the drug receiving portion (200). The first space (122) is formed on one side of the drug receiving portion (200) and may be in communication with the gas communication hole (112). The second space (123) is formed on the other side of the drug receiving portion (200) and the entry of gas generated from the foaming portion (110) may be blocked (by the drug receiving portion (200)).

[0047] In an embodiment, the gas receiving portion (120) may include a body fluid communication hole (124). For example, the body fluid communication hole (124) may communicate with a second space (123). For example, the body fluid communication hole (124) may be formed at the top of the gas receiving portion (120) (particularly at the top of the second space (123)). For example, the gas receiving portion (120) may normally be sealed through a separately provided plug, and then opened when a plurality of drug release devices (1000) need to be connected to each other.

[0048] The drug receiving portion (200) is provided on the inner side of the gas receiving portion (120) and can contain a drug inside. The drug contained in the drug receiving portion (200) is normally blocked from being released to the outside by the gas receiving portion (120) and the thin film portion (121), but can be released to the outside when the thin film portion (121) is opened.

[0049] In an example, the drug receiving portion (200) may include a receiving pocket (210) and an incision portion (220).

[0050] The receiving pocket (210) can receive drugs and may have a soft material. When the internal pressure of the gas receiving portion (120) increases, the receiving pocket (210) may bend toward the thin film portion (121). The receiving pocket (210) may be formed from all known types of soft materials, such as polyurethane (PU), polyethylene (PE), polypropylene (PP), ethylene vinyl acetate (EVA), and polycaprolactone (PCL).

[0051] The incision (220) may be formed to protrude toward the film portion (121) from one side of the receiving pocket (210). The incision (220) may move in conjunction with the curvature of the receiving pocket (210). When the receiving pocket (210) curves toward the film portion (121) as the internal pressure of the gas receiving portion (120) increases, the incision (220) may cut the film portion (121) (moving toward the film portion (121)).

[0052] In an embodiment, the drug receiving portion (200) may come into contact with the inner circumference of the gas receiving portion (120) along its circumference. Accordingly, the internal space of the gas receiving portion (120) may be divided into a first space (122) and a second space (123).

[0053] The body fluid delivery unit (300) is provided on the lower side of the foaming unit (110) and can deliver body fluid (inside the human body outside the drug release device (1000)) to the foaming unit (110). When the body fluid delivery unit (300) comes into contact with the body fluid, it can deliver the body fluid to the foaming unit (110) after a preset period has elapsed.

[0054] In an embodiment, the body fluid delivery unit (300) may include a decomposition wick (310). In this specification, "decomposition" is a general term for decomposition by chemical reaction, dissolution by a solvent, etc. The decomposition wick (310) may be positioned so that one end is exposed to the outside and the other end faces the foaming unit (110). When body fluid comes into contact with one end of the decomposition wick (310), the decomposition wick (310) is gradually decomposed by the body fluid, and when the body fluid reaches the other end and the other end is decomposed by the body fluid, the body fluid can be delivered to the foaming unit (110), particularly to the foaming tablet (111). For example, the decomposition wick (310) may include polylactide (PLA), polyglycolide (PGA), polylactide-co-glycolide (PLGA), polycaprolactone (PCL), polyvinyl alcohol (PVA), polyglutamic acid (PGA), polyhydroxyalkanoate (PHA), chitosan, polyethylene glycol (PEG), etc. as a material that decomposes by body fluids.

[0055] In the embodiment, the length of the disintegration wick (310) may be set by taking into account the disintegration speed of the disintegration wick (310) and the length of a preset period. For example, if the drug is to be released after a relatively long period has elapsed since the implantation of the drug release device (1000), the length of the disintegration wick (310) may be set to be long, and if the drug is to be released after a relatively short period has elapsed since the implantation of the drug release device (1000), the length of the disintegration wick (310) may be set to be short.

[0056] In the embodiment, the remaining portion of the disintegrating wick (310), excluding one end (exposed to the outside), may be blocked from contact with the outside. Accordingly, the disintegrating wick (310) may be able to initiate a reaction with body fluids only through the exposed end, and may not be able to initiate a reaction with body fluids through other portions. Through this, only the disintegration rate of the disintegrating wick (310) and the length of a preset period may serve as variables required to calculate the length of the disintegrating wick (310).

[0057] In the embodiment, all known types of coupling methods, such as screw coupling, snap coupling, locking coupling, adhesive coupling, compression coupling, and magnetic coupling, may be applied to the coupling between each component constituting the drug release device (1000).

[0058] The drug release device (1000) according to FIGS. 1 to 4 is exemplary, and various configurations may be applied according to the embodiments to which the present application applies.

[0059]

[0060] FIG. 5 is a drawing for explaining a body fluid delivery unit according to an embodiment of the present application.

[0061] Referring to FIG. 5, the length of the disintegration wick (310) of the body fluid delivery unit (300) can be set by taking into account the disintegration rate of the disintegration wick (310) and the length of a preset period. Specifically, FIG. 5 (a) illustrates the length of the disintegration wick (310) when the drug is to be released after the longest period has elapsed since the implantation of the drug release device (1000), FIG. 5 (b) illustrates the length of the disintegration wick (310) when the drug is to be released after an intermediate period has elapsed since the implantation of the drug release device (1000), and FIG. 5 (c) illustrates the length of the disintegration wick (310) when the drug is to be released after the shortest period has elapsed since the implantation of the drug release device (1000). In each case, the length of the disintegration wick (310) can be set in proportion to the length of the preset period.

[0062] The fluid delivery unit (300) according to FIG. 5 is exemplary, and various configurations may be applied according to the embodiments to which the present application applies.

[0063]

[0064] FIG. 6 is a diagram illustrating the drug release process of a drug release device according to an embodiment of the present application.

[0065] Referring to FIG. 6, when the drug release device (1000) is implanted in the body, the body fluid may come into contact with one end of the decomposition wick (310) of the body fluid delivery unit (300). Subsequently, as the decomposition wick (310) gradually decomposes and finally the other end of the decomposition wick (310) decomposes, the body fluid may pass through the body fluid delivery unit (300) and be delivered to the foaming unit (110). When the body fluid reaches the foaming unit (110), the body fluid and the foaming material contained in the foaming tablet (111) may react to generate gas, and the generated gas may move to the gas receiving unit (120) through the gas communication hole (112). Accordingly, when the internal pressure of the gas receiving portion (120) increases, the receiving pocket (210) of the drug receiving portion (200) bends toward the thin film portion (121) of the gas receiving portion (120), and accordingly, the incision portion (220) of the drug receiving portion (200) can cut the thin film portion (121). When the thin film portion (121) is cut, the drug contained within the receiving pocket (210) can be released to the outside through the cut portion of the thin film portion (121).

[0066] The drug release process of the drug release device (1000) according to FIG. 6 is exemplary, and various methods may be applied according to the embodiments to which the present application applies.

[0067]

[0068] FIG. 7 is a perspective view of a pulsed drug release kit according to an embodiment of the present application, and FIG. 8 is a cross-sectional view of a pulsed drug release kit according to an embodiment of the present application.

[0069] Referring to FIGS. 7 and 8, the pulsed drug release kit (2000) may be provided with two or more drug release devices (1000, 1000') connected. For example, the drug release devices (1000, 1000') may include a first drug release device (1000) and a second drug release device (1000'), and the pulsed drug release kit (2000) may be provided with the first drug release device (1000) and the second drug release device (1000') connected. The first drug release device (1000) and the second drug release device (1000') may be described in the same way as the drug release device (1000) of FIGS. 1 to 4. However, it is not limited to this, and the pulse-type drug release kit (3000) may be provided with a plurality of drug release devices (1000), such as a third drug release device and a fourth drug release device, additionally connected.

[0070] In the embodiment, after the pulsed drug release kit (2000) is implanted in the body, a drug may be released from the first drug release device (1000) after a preset first period has elapsed, and a drug may be released from the second drug release device (1000') after a preset second period has elapsed. That is, the release of the drug from the pulsed drug release kit (2000) may not be continuous over time but stepwise.

[0071] In the embodiments, the first period and the second period may be the same or different. For example, if the first drug must be released immediately after implantation in the body, but the second drug must be released after a long period has elapsed since the release of the first drug, the first period may be set short and the second period may be set long. In this case, the dissolution wick of the first drug release device (1000) may be provided short, and the dissolution wick of the second drug release device (1000') may be provided long. Conversely, if the first drug must be released after a long period has elapsed since implantation in the body, but the second drug must be released immediately after the release of the first drug, the first period may be set long and the second period may be set short. In this case, the dissolution wick of the first drug release device (1000) may be provided long, and the dissolution wick of the second drug release device (1000') may be provided short.

[0072] In an embodiment, a body fluid delivery part (300') of a second drug release device (1000') may be connected to the top of the main body part (100) of the first drug release device (1000).

[0073] In an embodiment, body fluid may flow into the body fluid delivery section (300') of the second drug release device (1000') through the body fluid communication hole (124) formed at the top of the main body section (100) of the first drug release device (1000). At this time, the body fluid delivery section (300') of the second drug release device (1000') receives body fluid only through the body fluid communication hole (124) of the first drug release device (1000), and the delivery of body fluid from the outside may be blocked.

[0074] In an embodiment, after the thin film portion (121) of the first drug release device (1000) is cut and body fluid flows into the second space (123) of the first drug release device (1000), the body fluid can be transferred to the body fluid delivery portion (300') of the second drug release device (1000') through the body fluid communication hole (124) of the first drug release device (1000). At this time, when the thin film portion (121) of the first drug release device (1000) is not cut, body fluid may not flow into the second drug release device (1000') through the body fluid communication hole (124).

[0075] In the embodiment, all known types of coupling methods, such as screw coupling, snap coupling, locking coupling, adhesive coupling, compression coupling, and magnetic coupling, may be applied to the coupling between each component constituting the pulsed drug release kit (2000).

[0076] The pulsed drug release kit (2000) in FIGS. 7 and 8 is exemplary, and various configurations may be applied according to the embodiments to which the present application applies.

[0077]

[0078] FIG. 9 is a diagram illustrating the drug release process of a pulsed drug release kit according to an embodiment of the present application.

[0079] Referring to FIG. 9, when a pulsed drug release kit (2000) is implanted in the body, body fluid may come into contact with one end of the decomposition wick (310) of the body fluid delivery section (300) of the first drug release device (1000). Subsequently, as the decomposition wick (310) gradually decomposes and finally the other end of the decomposition wick (310) decomposes, the body fluid may pass through the body fluid delivery section (300) and be delivered to the foaming section (110). When the body fluid reaches the foaming section (110), the body fluid and the foaming material contained in the foaming tablet (111) may react to generate gas, and the generated gas may move to the gas receiving section (120) through the gas communication hole (112). Accordingly, when the internal pressure of the gas receiving portion (120) increases, the receiving pocket (210) of the drug receiving portion (200) bends toward the thin film portion (121) of the gas receiving portion (120), and accordingly, the incision portion (220) of the drug receiving portion (200) can cut the thin film portion (121). When the thin film portion (121) is cut, the drug contained within the receiving pocket (210) can be released to the outside through the cut portion of the thin film portion (121).

[0080] When the thin film portion (121) of the first drug release device (1000) is cut, body fluid can flow into the second space (123) through the cut area of ​​the thin film portion (121) of the first drug release device (1000), and body fluid can come into contact with one end of the decomposition wick (310') of the body fluid delivery portion (300') of the second drug release device (1000') through the body fluid communication hole (124) of the first drug release device (1000). Subsequently, the second drug release device (1000') can release the drug to the outside through the same process as the first drug release device (1000).

[0081] The drug release process of the pulsed drug release kit (2000) according to FIG. 9 is exemplary, and various methods may be applied according to the embodiments to which the present application applies.

[0082]

[0083] As described above, embodiments have been disclosed in the drawings and specification. Those skilled in the art will understand that various modifications and equivalent alternative embodiments are possible therefrom. Accordingly, the substantial scope of this application shall be defined by the appended claims and their equivalents.

Claims

As a drug release device, A main body comprising: a foaming part that reacts with body fluids to generate gas; and a gas receiving part provided above the foaming part to receive the gas generated from the foaming part; A drug receiving portion provided on the inner side of the above gas receiving portion and containing a drug inside; and A body fluid delivery unit provided on the lower side of the foaming unit and delivering body fluid to the foaming unit; is included. The above-mentioned body fluid delivery unit delivers the body fluid to the foaming unit after a preset period has elapsed upon contact with the body fluid, and A drug release device in which, as the gas is generated from the foaming part, the internal pressure of the gas receiving part increases, and the drug contained in the drug receiving part is released to the outside. In Article 1, The above main body part is provided on one surface of the gas receiving part and includes a thin film part that shields at least one surface of the gas receiving part from the outside. The above drug receiving portion comprises: a soft receiving pocket in which the drug is received; and an incision formed to protrude toward the thin film portion from one side of the receiving pocket. A drug release device in which, when the internal pressure of the gas receiving portion increases, the receiving pocket bends toward the thin film portion, thereby cutting the thin film portion and releasing the drug to the outside. In Article 1, The above-mentioned fluid delivery unit includes a disintegrating wick positioned such that one end is exposed to the outside and the other end faces the foaming unit, and A drug release device in which, when the body fluid comes into contact with the one end, the decomposition wick is gradually decomposed by the body fluid, and when the body fluid reaches the other end and the other end is decomposed by the body fluid, the body fluid is delivered to the foaming part. In Paragraph 3, A drug release device in which the length of the above-mentioned decomposition wick is set by taking into account the decomposition speed of the above-mentioned decomposition wick and the length of the above-mentioned preset period. In Paragraph 3, A drug release device in which the remaining portion, excluding the one end portion of the above-mentioned disintegration wick, is blocked from contact with the outside. In Article 1, A drug release device comprising: a foaming tablet containing a foaming material that reacts with at least one substance contained in a body fluid to generate gas; and a gas communication hole communicating the internal space of the foaming tablet and the gas receiving portion. In Article 1, The above drug receiving portion contacts the inner circumference of the gas receiving portion along its circumference, thereby dividing the internal space of the gas receiving portion, and The internal space of the gas receiving portion comprises: a first space formed on one side of the drug receiving portion and communicating with the gas communication hole; and a second space formed on the other side of the drug receiving portion and blocking the entry of gas generated from the foaming portion. A drug release device having a body fluid communication hole formed at the top of the gas receiving portion that communicates with the second space. In Article 1, The above drug-releasing device is a drug-releasing device that is implanted in the body. A pulse-type drug release kit having two or more drug release devices of any one of claims 1 to 8 connected together. In Article 9, The above drug release device includes a first drug release device and a second drug release device, and A pulse-type drug release kit in which the fluid delivery part of the second drug release device is connected to the upper part of the main body of the first drug release device.

Images